Cargando…
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
INTRODUCTION: Osimertinib may be effective in treating central nervous system (CNS) metastasis, but its efficacy in treating radiation therapy (RT)-naive metastasis is unclear. The OCEAN study assessed the efficacy of osimertinib against RT-naive CNS metastasis in patients previously treated (T790M...
Autores principales: | Wakuda, Kazushige, Yamaguchi, Hiroyuki, Kenmotsu, Hirotsugu, Fukuda, Minoru, Ito, Kentaro, Tsuchiya-Kawano, Yuko, Tanaka, Kentaro, Harada, Taishi, Nakatani, Yuki, Miura, Satoru, Yokoyama, Toshihide, Nakamura, Tomomi, Izumi, Miiru, Nakamura, Atsushi, Ikeda, Satoshi, Takayama, Koichi, Yoshimura, Kenichi, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki, Sugio, Kenji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689268/ https://www.ncbi.nlm.nih.gov/pubmed/38046380 http://dx.doi.org/10.1016/j.jtocrr.2023.100587 |
Ejemplares similares
-
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)
por: Wakuda, Kazushige, et al.
Publicado: (2020) -
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
por: Wakuda, Kazushige, et al.
Publicado: (2023) -
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)
por: Miyawaki, Taichi, et al.
Publicado: (2021) -
Digitale Logik
por: Stuckenberg, Hans Joachim
Publicado: (1970) -
Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
por: Kawamura, Takahisa, et al.
Publicado: (2019)